Reaching the threshold: A multilayer pathogenesis of macrophage activation syndrome

Raffaele Strippoli, Ivan Caiello, Fabrizio De Benedetti

Research output: Contribution to journalArticle

Abstract

Macrophage activation syndrome (MAS) is a potentially fatal complication of rheumatic diseases. The condition is considered part of secondary hemophagocytic lymphohistiocytoses (HLH). There are similarities in genetic background, pathogenesis, and clinical and laboratory features with primary HLH (p-HLH). We describe findings in mouse models of secondary HLH, comparing them with models of p-HLH and the cellular and molecular mechanisms involved, and relate them to recent findings in patients with secondary HLH. A multilayer model is presented in which background inflammation, infections, and genetics all contribute in different proportions and in several ways. Once the "threshold" has been reached, inflammatory cytokines are the final effectors, independent of the interplay between different upstream pathogenic factors.

Original languageEnglish
Pages (from-to)761-767
Number of pages7
JournalJournal of Rheumatology
Volume40
Issue number6
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Macrophage Activation Syndrome
Hemophagocytic Lymphohistiocytosis
Rheumatic Diseases
Cytokines
Inflammation
Infection

Keywords

  • Etiology
  • Hemophagocytic Lymphohistiocytoses
  • Juvenile Idiopathic Arthritis
  • Macrophage Activation Syndrome

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Reaching the threshold : A multilayer pathogenesis of macrophage activation syndrome. / Strippoli, Raffaele; Caiello, Ivan; De Benedetti, Fabrizio.

In: Journal of Rheumatology, Vol. 40, No. 6, 06.2013, p. 761-767.

Research output: Contribution to journalArticle

@article{ba50540bfa5144fab9ad3a29d0bacdf4,
title = "Reaching the threshold: A multilayer pathogenesis of macrophage activation syndrome",
abstract = "Macrophage activation syndrome (MAS) is a potentially fatal complication of rheumatic diseases. The condition is considered part of secondary hemophagocytic lymphohistiocytoses (HLH). There are similarities in genetic background, pathogenesis, and clinical and laboratory features with primary HLH (p-HLH). We describe findings in mouse models of secondary HLH, comparing them with models of p-HLH and the cellular and molecular mechanisms involved, and relate them to recent findings in patients with secondary HLH. A multilayer model is presented in which background inflammation, infections, and genetics all contribute in different proportions and in several ways. Once the {"}threshold{"} has been reached, inflammatory cytokines are the final effectors, independent of the interplay between different upstream pathogenic factors.",
keywords = "Etiology, Hemophagocytic Lymphohistiocytoses, Juvenile Idiopathic Arthritis, Macrophage Activation Syndrome",
author = "Raffaele Strippoli and Ivan Caiello and {De Benedetti}, Fabrizio",
year = "2013",
month = "6",
doi = "10.3899/jrheum.121233",
language = "English",
volume = "40",
pages = "761--767",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "6",

}

TY - JOUR

T1 - Reaching the threshold

T2 - A multilayer pathogenesis of macrophage activation syndrome

AU - Strippoli, Raffaele

AU - Caiello, Ivan

AU - De Benedetti, Fabrizio

PY - 2013/6

Y1 - 2013/6

N2 - Macrophage activation syndrome (MAS) is a potentially fatal complication of rheumatic diseases. The condition is considered part of secondary hemophagocytic lymphohistiocytoses (HLH). There are similarities in genetic background, pathogenesis, and clinical and laboratory features with primary HLH (p-HLH). We describe findings in mouse models of secondary HLH, comparing them with models of p-HLH and the cellular and molecular mechanisms involved, and relate them to recent findings in patients with secondary HLH. A multilayer model is presented in which background inflammation, infections, and genetics all contribute in different proportions and in several ways. Once the "threshold" has been reached, inflammatory cytokines are the final effectors, independent of the interplay between different upstream pathogenic factors.

AB - Macrophage activation syndrome (MAS) is a potentially fatal complication of rheumatic diseases. The condition is considered part of secondary hemophagocytic lymphohistiocytoses (HLH). There are similarities in genetic background, pathogenesis, and clinical and laboratory features with primary HLH (p-HLH). We describe findings in mouse models of secondary HLH, comparing them with models of p-HLH and the cellular and molecular mechanisms involved, and relate them to recent findings in patients with secondary HLH. A multilayer model is presented in which background inflammation, infections, and genetics all contribute in different proportions and in several ways. Once the "threshold" has been reached, inflammatory cytokines are the final effectors, independent of the interplay between different upstream pathogenic factors.

KW - Etiology

KW - Hemophagocytic Lymphohistiocytoses

KW - Juvenile Idiopathic Arthritis

KW - Macrophage Activation Syndrome

UR - http://www.scopus.com/inward/record.url?scp=84878666042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878666042&partnerID=8YFLogxK

U2 - 10.3899/jrheum.121233

DO - 10.3899/jrheum.121233

M3 - Article

C2 - 23588947

AN - SCOPUS:84878666042

VL - 40

SP - 761

EP - 767

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 6

ER -